Trillium Therapeutics Reports First Quarter 2021 Operating and Financial Results
Trillium Therapeutics Inc. a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results for the three months ended March 31, 2021. All financial amounts in this news release are in United States dollars, unless otherwise stated. “Coming off an R&D Day last week, we are very excited to have launched a new chapter in Trillium’s …
Trillium Therapeutics Inc. (NASDAQTSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results for the three months ended March 31, 2021. All financial amounts in this news release are in United States dollars, unless otherwise stated.
Trillium: Q1 Earnings Snapshot
FacebookTwitterEmail
MISSISSAUGA, Ontario (AP) Trillium Therapeutics Inc. (TRIL) on Friday reported a loss of $10.9 million in its first quarter.
The Mississauga, Ontario-based company said it had a loss of 11 cents per share.
Trillium shares have decreased 37% since the beginning of the year. The stock has risen 74% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on TRIL at https://www.zacks.com/ap/TRIL Top Picks In Shopping
Trillium Therapeutics (TSX:TRIL): A Pharma Stock With Huge Upside Potential
More on:
Trillium Therapeutics (TSX:TRIL)(NASDAQ:TRIL) is a Canadian pharmaceutical stock that has
massive upside potential and should be on your radar right now. The clinical-stage immuno-oncology company is developing revolutionary cancer treatment therapies, and it could be an excellent value pick for investors today.
I will discuss the company and why its stock could be an ideal investment for you to consider.
A leading innovator in oncology
Trillium Therapeutics may not be as big a name as
Pfizer, but it is not a company to shrug aside. The company aims to become a leading innovator in oncology by using innovative therapies targeting immune-regulatory pathways used by tumour cells to steer clear of the immune system.
By Reuters Staff
(Updates prices, adds sectors)
April 28 (Reuters) - Canada’s main stock index climbed on Wednesday, supported by higher oil prices and upbeat February retail sales data, even as investors awaited the outcome of the U.S. Federal Reserve policy meet.
Most Fed watchers expect Chairman Jerome Powell to repeat the bank’s recent message that its low interest rates and support programmes will remain in place for a long time. At 9:40 a.m. ET (13:40 GMT), the Toronto Stock Exchange’s S&P/TSX composite index was up 101.28 points, or 0.53%, at 19,276.37. Shopify Inc, reported a 110% jump in first-quarter revenue, as its e-commerce platform profited from the past year’s COVID-19 driven boom in online selling.
Trillium Therapeutics is up against some stiff competition to become a leader in the new class of drugs called CD47, which turn off the “don’t eat me” signal transmitted by cancer cells, but CEO Jan Skvarka believes his biotech’s data will stand for themselves.